TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from 4SC AG ( (DE:VSC) ).
4SC AG has received feedback from the European Medicines Agency (EMA) regarding its Marketing Authorization Application for Resminostat (Kinselby). The company has been invited to provide an Oral Explanation before the Committee for Medicinal Products for Human Use, which will decide on the application at the end of May. This development is crucial for 4SC’s market positioning in the EU and could significantly impact its operations and stakeholder interests depending on the outcome.
More about 4SC AG
4SC AG is a biotechnology company based in Planegg-Martinsried, Germany. It is listed on the Frankfurt Stock Exchange and focuses on developing small molecule drugs for cancer and autoimmune diseases. The company’s key product, Resminostat (Kinselby), is under review for market authorization in the European Union.
Technical Sentiment Signal: Buy
Current Market Cap: €31.08M
Learn more about VSC stock on TipRanks’ Stock Analysis page.